Biogen Inc. (BIIB) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Drug Manufacturers - General
Biogen Inc. (BIIB) Profile & Business Summary
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Key Information
| Ticker | BIIB |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.biogen.com |
Market Trend Overview for BIIB
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-07-14 (ET)
As of 2026-07-14, BIIB is showing signs of slowing down. Over the longer term, the trend remains bullish.
BIIB last closed at 191.95. The price is about 1.8 ATR below its recent average price (202.65), and the market is currently in a trend that may be losing strength. Price at 191.95 is near minor support around 184.90. Momentum may slow, while light resistance sits near 192.28. View Support & Resistance from Options
The broader uptrend is still intact, but price has moved far from its recent average, increasing the risk of a pullback.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside risk boundary is near 181.03. If price falls below this area, the current structure would likely weaken further.
On 2026-07-14, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-06-01] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not deploy this setup because predictability is still too low, price is still close to a gamma transition zone, and the setup already looks stretched. Predictability is 29%, agreement is 71%, and reversal risk is 45%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is trading 5.2% below the recent estimated cost basis of 202.59, so the recent structure is still leaning under pressure. Price is below the main cost band (194.04 to 202.80), and roughly 92% of recent positioning remains under water. That means rebounds can still run into supply from trapped holders. The broader structure still looks stretched on the weak side, so recovery attempts may need more proof before improving the tone. The higher up selling area sits around 206.75 to 211.13, so rebounds may begin to slow as price pushes into that zone. The main cost band is fairly wide relative to recent ATR, so this structure may behave less cleanly than a tighter setup. From a trading point of view, this setup remains tougher until price can reclaim the lower edge of the main cost band near 194.04.